Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQA3810 in Chronic Hepatitis B
NCT06566248Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQA3810 in Chronic Hepatitis B (CHB), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Incidence and severity of adverse events and serious adverse events at 52 months. Started Mar 2024; status: recruiting.
02
Drugs
TQA3810
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06566248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566248.